RU2355687C2 - Бициклические производные имидазола в качестве средства против вирусов семейства flaviviridae - Google Patents

Бициклические производные имидазола в качестве средства против вирусов семейства flaviviridae Download PDF

Info

Publication number
RU2355687C2
RU2355687C2 RU2006106272/04A RU2006106272A RU2355687C2 RU 2355687 C2 RU2355687 C2 RU 2355687C2 RU 2006106272/04 A RU2006106272/04 A RU 2006106272/04A RU 2006106272 A RU2006106272 A RU 2006106272A RU 2355687 C2 RU2355687 C2 RU 2355687C2
Authority
RU
Russia
Prior art keywords
cyclohexyl
benzoimidazole
carboxylic acid
quinolin
substituted
Prior art date
Application number
RU2006106272/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2006106272A (ru
Inventor
Франц Ульрих ШМИТЦ (US)
Франц Ульрих Шмитц
Кристофер Дон РОБЕРТС (US)
Кристофер Дон Робертс
Роналд Конрад ГРИФФИТ (US)
Роналд Конрад ГРИФФИТ
Янош БОТЯНСКИ (US)
Янош БОТЯНСКИ
Микаил Хакан ГЕЗГИНЧИ (US)
Микаил Хакан ГЕЗГИНЧИ
Джошуа Майкл ГРАЛАПП (US)
Джошуа Майкл ГРАЛАПП
Дун-Фан ШИ (US)
Дун-Фан ШИ
Себастьян Й. Р. ЛИР (US)
Себастьян Й. Р. ЛИР
Original Assignee
Дженелэбс Текнолоджиз, Инк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженелэбс Текнолоджиз, Инк filed Critical Дженелэбс Текнолоджиз, Инк
Publication of RU2006106272A publication Critical patent/RU2006106272A/ru
Application granted granted Critical
Publication of RU2355687C2 publication Critical patent/RU2355687C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2006106272/04A 2003-08-01 2004-07-30 Бициклические производные имидазола в качестве средства против вирусов семейства flaviviridae RU2355687C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49210803P 2003-08-01 2003-08-01
US60/492,108 2003-08-01

Publications (2)

Publication Number Publication Date
RU2006106272A RU2006106272A (ru) 2006-08-27
RU2355687C2 true RU2355687C2 (ru) 2009-05-20

Family

ID=34115596

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006106272/04A RU2355687C2 (ru) 2003-08-01 2004-07-30 Бициклические производные имидазола в качестве средства против вирусов семейства flaviviridae

Country Status (14)

Country Link
US (2) US7511145B2 (enExample)
EP (1) EP1651631A1 (enExample)
JP (1) JP2007501189A (enExample)
KR (1) KR20060054410A (enExample)
CN (1) CN1829709A (enExample)
AU (1) AU2004261667A1 (enExample)
BR (1) BRPI0413234A (enExample)
CA (1) CA2534649A1 (enExample)
IL (1) IL172975A0 (enExample)
NO (1) NO20061013L (enExample)
RU (1) RU2355687C2 (enExample)
TW (1) TW200517381A (enExample)
WO (1) WO2005012288A1 (enExample)
ZA (1) ZA200600424B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2533825C2 (ru) * 2009-06-11 2014-11-20 Сиена Байотек С.П.А. ПРОИЗВОДНЫЕ БЕНЗИМИДАЗОЛА И ИМИДАЗО[4,5-с]ПИРИДИНА, В КАЧЕСТВЕ АНТАГОНИСТА ПУТИ HEDGEHOG
RU2702906C2 (ru) * 2012-05-30 2019-10-14 Астекс Терапьютикс Лимитед Птеридины в качестве fgfr ингибиторов

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
PL374971A1 (en) 2002-08-09 2005-11-14 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
CN1829709A (zh) 2003-08-01 2006-09-06 健亚生物科技公司 对抗黄病毒的双环咪唑衍生物
WO2005014532A1 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
US7208601B2 (en) * 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
US7485658B2 (en) * 2003-08-21 2009-02-03 Osi Pharmaceuticals, Inc. N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
IN2012DN04853A (enExample) 2004-02-20 2015-09-25 Boehringer Ingelheim Int
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
WO2006076529A1 (en) * 2005-01-14 2006-07-20 Genelabs Technologies, Inc. Indole derivatives for treating viral infections
RU2466126C2 (ru) * 2005-02-11 2012-11-10 Берингер Ингельхайм Интернациональ Гмбх Способ получения 2,3-дизамещенных индолов
PT1928454E (pt) 2005-05-10 2014-12-04 Intermune Inc Derivativos da piridona para modulação do sistema de proteína quinase ativada pelo stress
AU2006261132A1 (en) * 2005-06-24 2006-12-28 Genelabs Technologies, Inc. Heteroaryl derivatives for treating viruses
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
WO2007019674A1 (en) 2005-08-12 2007-02-22 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
FR2892719B3 (fr) * 2005-11-02 2008-01-18 Sep Innovaterm Barriere physico-chimique anti-termites constituee par du beton dans lequel a ete incorpore dans toute la masse un insecticide contre les termites
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP1988776B1 (en) * 2006-03-02 2012-08-08 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
US7977365B2 (en) * 2006-03-02 2011-07-12 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
US8871746B2 (en) 2006-03-02 2014-10-28 Kineta Four, LLC Antiviral drugs for treatment of arenavirus infection
KR20080105112A (ko) * 2006-03-27 2008-12-03 이데미쓰 고산 가부시키가이샤 함질소 복소환 유도체 및 그것을 이용한 유기 전기발광 소자
WO2007133865A2 (en) 2006-04-11 2007-11-22 Novartis Ag Hcv/hiv inhibitors an their uses
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
KR20090029827A (ko) * 2006-07-20 2009-03-23 제네랩스 테크놀로지스, 인코포레이티드 폴리사이클릭 바이러스 억제제
BRPI0716060A2 (pt) 2006-08-17 2013-09-17 Boehringer Ingelheim Int inibidores de polimerase viral.
CA2677001A1 (en) * 2006-08-23 2008-02-28 Xtl Biopharmaceuticals Ltd. 4-thio substituted quinoline and naphthyridine compounds
GB0619611D0 (en) * 2006-10-04 2006-11-15 Ark Therapeutics Ltd Compounds and their use
US8383662B2 (en) * 2006-12-05 2013-02-26 National Chiao Tung University Bicyclic heteroaryl compounds
SG144809A1 (en) 2007-01-11 2008-08-28 Millipore U K Ltd Benzimidazole compounds and their use as chromatographic ligands
JP2010529031A (ja) * 2007-05-29 2010-08-26 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害剤としてのナフチリジン誘導体
EP2188274A4 (en) 2007-08-03 2011-05-25 Boehringer Ingelheim Int VIRAL POLYMERASE HEMMER
US8143276B2 (en) 2007-08-22 2012-03-27 Xtl Biopharmaceuticals Ltd. 4-thio substituted quinoline and naphthyridine compounds
PL2203431T3 (pl) * 2007-09-17 2012-01-31 Abbvie Bahamas Ltd Pirymidyny o działaniu przeciw zakaźnym oraz ich zastosowania
US8940730B2 (en) 2007-09-18 2015-01-27 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a Flaviviridae family viral infection
US9101628B2 (en) 2007-09-18 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and composition of treating a flaviviridae family viral infection
US9149463B2 (en) 2007-09-18 2015-10-06 The Board Of Trustees Of The Leland Standford Junior University Methods and compositions of treating a Flaviviridae family viral infection
JP5715820B2 (ja) 2007-09-18 2015-05-13 スタンフォード ユニバーシティー フラビウイルス科ファミリーのウイルスへの感染を治療する方法ならびに、フラビウイルス科ファミリーのウイルスへの感染を治療するための組成物
CN101977621A (zh) 2007-12-05 2011-02-16 益安药业 氟化三肽hcv丝氨酸蛋白酶抑制剂
EA201000948A1 (ru) 2007-12-19 2011-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы вирусной полимеразы
KR101467615B1 (ko) * 2007-12-27 2014-12-01 이데미쓰 고산 가부시키가이샤 질소 함유 헤테로환 유도체 및 그것을 이용한 유기 전기발광 소자
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0919288A2 (pt) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012513410A (ja) 2008-12-23 2012-06-14 アボット・ラボラトリーズ 抗ウイルス化合物
MX2011006332A (es) 2008-12-23 2011-06-27 Abbott Lab Compuestos antivirales.
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
MX2011007195A (es) 2009-01-07 2013-07-12 Scynexis Inc Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
EP2408449A4 (en) * 2009-03-18 2012-08-08 Univ Leland Stanford Junior METHOD AND COMPOSITIONS FOR TREATING FLAVIVIRIDAE VIRUS INFECTIONS
US8268820B2 (en) 2009-03-26 2012-09-18 Hoffmann-La Roche Inc. 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
EP2419404B1 (en) 2009-04-15 2015-11-04 AbbVie Inc. Anti-viral compounds
MX2011012155A (es) 2009-05-13 2012-02-28 Enanta Pharm Inc Compuestos macrociclicos como inhibidores del virus de hepatitis c.
RU2407738C1 (ru) * 2009-07-03 2010-12-27 Общество с ограниченной ответственностью "Интеллектуальный Диалог" Противовирусный активный компонент, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
PE20120993A1 (es) 2009-09-04 2012-08-22 Janssen Pharmaceuticals Inc Derivados bifenilicos como antivirales
NZ598465A (en) 2009-10-30 2013-10-25 Boehringer Ingelheim Int Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
PH12012501037A1 (en) 2009-11-27 2013-01-14 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
JP5690839B2 (ja) 2009-12-04 2015-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン産生のベンゾイミダゾール阻害薬
AR082453A1 (es) 2010-04-21 2012-12-12 Novartis Ag Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
CA2797310C (en) 2010-05-05 2020-03-31 Boehringer Ingelheim International Gmbh Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
CA2806108A1 (en) 2010-07-22 2012-01-26 Novartis Ag 2,3,5-trisubstituted thiophene compounds and uses thereof
SG188618A1 (en) 2010-09-21 2013-04-30 Enanta Pharm Inc Macrocyclic proline derived hcv serine protease inhibitors
BR112013007423A2 (pt) * 2010-09-30 2016-07-12 Boehringer Ingelheim Int terapia combinada no que diz respeito ao tratamento da infecção por hcv
AU2011311880B2 (en) 2010-10-08 2014-07-24 Novartis Ag Vitamin E formulations of sulfamide NS3 inhibitors
JP5928958B2 (ja) 2010-10-29 2016-06-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成のベンゾイミダゾールインヒビター
JP5789888B2 (ja) * 2010-11-01 2015-10-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成のベンゾイミダゾールインヒビター
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
ES2713566T3 (es) 2011-07-15 2019-05-22 Boehringer Ingelheim Int Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
KR101469127B1 (ko) * 2013-03-11 2014-12-04 한양대학교 에리카산학협력단 신규 벤즈이미다졸 유도체, 이의 이성질체 또는 이의 약학적으로 허용 가능한 염, 및 이를 포함하는 약학 조성물
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
MX370099B (es) 2014-03-26 2019-12-02 Astex Therapeutics Ltd Combinación que comprende un inhibidor de fgfr y un inhibidor de cmet para el tratamiento del cáncer.
KR102479696B1 (ko) 2014-03-26 2022-12-22 아스텍스 테라퓨틱스 리미티드 Fgfr 억제제 및 igf1r 억제제의 조합물
KR102373700B1 (ko) 2014-04-02 2022-03-11 인터뮨, 인크. 항섬유성 피리디논
CN107427506A (zh) * 2014-10-14 2017-12-01 拉霍拉敏感及免疫学研究所 低分子量蛋白酪氨酸磷酸酶的抑制剂及其用途
WO2016077541A1 (en) * 2014-11-12 2016-05-19 The Trustees Of The University Of Pennsylvania Novel anti-infective compounds and methods using same
WO2016130501A1 (en) * 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
ES2877424T3 (es) * 2015-07-07 2021-11-16 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts 2-Aril- y 2-arilalquil-bencimidazoles como inhibidores de MIDH1
JP2018525371A (ja) * 2015-07-30 2018-09-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アリール置換された二環式ヘテロアリール化合物
KR102691777B1 (ko) 2015-09-23 2024-08-02 얀센 파마슈티카 엔브이 비-헤테로아릴 치환된 1,4-벤조디아제핀 및 암의 치료를 위한 이의 용도
CA2996857C (en) 2015-09-23 2024-05-21 Janssen Pharmaceutica Nv Quinoxaline, quinoline and quinazolinone derivative compounds for the treatment of cancer
AR106595A1 (es) 2015-11-06 2018-01-31 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
CN108697709A (zh) 2015-12-10 2018-10-23 Ptc医疗公司 用于治疗亨廷顿病的方法
EP3400221B1 (en) 2016-01-05 2020-08-26 Incyte Corporation Pyrazol / imidazol substituted pyridines as pi3k-gamma inhibitors
CN106946775B (zh) * 2016-01-07 2020-04-10 清华大学 一种化合物及其在制备抗丙肝病毒药物中的应用
CN113549110B (zh) 2016-04-07 2024-08-16 葛兰素史密斯克莱知识产权发展有限公司 用作蛋白质调节剂的杂环酰胺
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
TW201803871A (zh) 2016-06-24 2018-02-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
JP7058256B2 (ja) 2016-07-14 2022-04-21 ブリストル－マイヤーズ スクイブ カンパニー 二環式ヘテロアリール置換化合物
WO2018013776A1 (en) 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as par4 inhibitors
US10730868B2 (en) 2016-07-14 2020-08-04 Bristol-Myers Squibb Company Bicyclic heteroaryl substituted compounds
EP3615529B1 (en) 2017-04-26 2024-06-05 Basilea Pharmaceutica International AG, Allschwil Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof
EP3619210A4 (en) 2017-05-01 2020-12-02 Sanford Burnham Prebys Medical Discovery Institute LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) INHIBITORS AND ASSOCIATED USES
AU2018282154B2 (en) 2017-06-05 2022-04-07 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
WO2019005993A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. METHODS OF TREATING HUNTINGTON'S DISEASE
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
BR112020007593A2 (pt) 2017-10-18 2020-09-24 Incyte Corporation derivados de imidazol condensados substituídos por grupos hidróxi terciários como inibidores de pi3k-gama
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
EP3814360B8 (en) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
WO2020005877A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
CN110105337B (zh) * 2019-05-31 2022-12-23 湖南大学 一种喹啉类三芳基胺及其制备方法
CN114761405A (zh) * 2019-11-29 2022-07-15 南京明德新药研发有限公司 抗hbv的1,7-萘啶类化合物
WO2022204452A1 (en) * 2021-03-26 2022-09-29 Cedilla Therapeutics, Inc. Tead inhibitors and uses thereof
CN115850672B (zh) * 2022-11-25 2024-07-19 浙江甬仑聚嘉新材料有限公司 一种液晶聚合物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329459A (en) * 1980-05-05 1982-05-11 The Upjohn Company Tetrahydrobenzopyran derivatives
RU2193561C2 (ru) * 1991-05-02 2002-11-27 Джон Вайс энд Бразер Лимитед Производные пиперазина, способ их получения, фармацевтическая композиция, промежуточное соединение

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1584735A (enExample) * 1968-03-20 1970-01-02
CH632628B (de) * 1976-07-26 Ciba Geigy Ag Verfahren zur herstellung von benzofuranyl-benzimidazolen und deren verwendung als optische aufheller.
DE2721190A1 (de) * 1977-05-11 1978-11-16 Bayer Ag Kationische farbstoffe
DE2964427D1 (en) 1978-10-04 1983-02-03 Ciba Geigy Ag Process for the preparation of furanyl-benzazoles
JPH0772181B2 (ja) 1989-06-26 1995-08-02 株式会社大塚製薬工場 ベンズイミダゾール誘導体
FR2674855B1 (fr) * 1991-04-03 1994-01-14 Synthelabo Derives de piperidine, leur preparation et leur application en therapeutique.
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
DE4304650A1 (de) 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
PE27997A1 (es) 1994-04-29 1997-09-20 Lilly Co Eli Antagonistas de receptores de taquicininas
US5563143A (en) * 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
WO1996035713A1 (en) 1995-05-08 1996-11-14 Pfizer, Inc. Dipeptides which promote release of growth hormone
EA002357B1 (ru) * 1995-12-28 2002-04-25 Фудзисава Фармасьютикал Ко., Лтд. Производные бензимидазола
GB9600142D0 (en) 1996-01-05 1996-03-06 Wellcome Found Chemical compounds
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5892743A (en) * 1996-04-02 1999-04-06 Matsushita Electric Industrial Co., Ltd. Information reproducing method and apparatus with servo characteristic change for sound reproduction
DE19615262A1 (de) * 1996-04-18 1997-10-23 Bayer Ag Heteroverknüpfte Phenylglycinolamide
JP2000511899A (ja) 1996-06-05 2000-09-12 イーライ・リリー・アンド・カンパニー 抗―ウイルス性化合物群
US6207679B1 (en) * 1997-06-19 2001-03-27 Sepracor, Inc. Antimicrobial agents uses and compositions related thereto
ZA987554B (en) 1997-08-21 2000-02-21 American Home Prod Methods for the solid phase synthesis of substituted indole compounds.
US5932743A (en) * 1997-08-21 1999-08-03 American Home Products Corporation Methods for the solid phase synthesis of substituted indole compounds
CN1299358A (zh) * 1997-12-31 2001-06-13 新泽西州州立大学(拉特格斯) 杂环拓扑异构酶毒性剂
CA2383983C (en) * 1998-03-31 2009-09-29 The Institutes For Pharmaceutical Discovery, Llc Substituted indolealkanoic acids
AU3379199A (en) 1998-04-03 1999-10-25 Regents Of The University Of Michigan, The Arabinofuranosyl benzimidazoles as antiviral agents
US6211177B1 (en) * 1998-11-24 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
US6358992B1 (en) * 1998-11-25 2002-03-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with indole derivatives
US6358986B1 (en) * 1999-01-19 2002-03-19 Boehringer Ingelheim Pharma Kg Polymorphs of telmisartan
GB9914825D0 (en) * 1999-06-24 1999-08-25 Smithkline Beecham Spa Novel compounds
EP1214330A1 (en) 1999-09-21 2002-06-19 LION Bioscience AG Benzimidazole derivatives and combinatorial libraries thereof
SK13752001A3 (sk) 1999-12-27 2002-07-02 Japan Tobacco, Inc. Zlúčeniny s fúzovanými kruhmi a ich použitie ako liečiv
US6770666B2 (en) * 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
GB0003397D0 (en) * 2000-02-14 2000-04-05 Merck Sharp & Dohme Therapeutic agents
WO2001064646A2 (en) * 2000-03-01 2001-09-07 Tularik Inc. Hydrazones and analogs as cholesterol lowering agents
US6310212B1 (en) * 2000-03-28 2001-10-30 Neurogen Corporation 4-substituted quinoline derivatives
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
AU2001271531A1 (en) * 2000-06-27 2002-01-08 Smith Kline Beecham Corporation Fatty acid synthase inhibitors
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
BR0113930A (pt) * 2000-09-15 2003-06-24 Anormed Inc Compostos heterocìclicos de ligação aos receptores de quimiocina
WO2002051837A2 (en) 2000-12-22 2002-07-04 Wyeth Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands
HUP0400726A3 (en) 2001-01-22 2007-05-29 Merck & Co Inc Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
EP1363632B1 (en) * 2001-01-29 2010-08-25 The University of Connecticut Receptor selective cannabimimetic aminoalkylindoles
US20050038022A1 (en) * 2001-03-26 2005-02-17 Unisearch Limited Method for treatment of cancer and compositions for use therein
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
CA2448737C (en) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US7294457B2 (en) 2001-08-07 2007-11-13 Boehringer Ingelheim (Canada) Ltd. Direct binding assay for identifying inhibitors of HCV polymerase
AU2002341715A1 (en) 2001-09-17 2003-04-01 Bristol-Myers Squibb Company Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
WO2003026587A2 (en) 2001-09-26 2003-04-03 Bristol-Myers Squibb Company Compounds useful for treating hepatitus c virus
FR2831536A1 (fr) * 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
US6737432B2 (en) * 2001-10-31 2004-05-18 Boehringer Ingelheim Pharma Kg Crystalline form of telmisartan sodium
SE0104331D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Novel compounds
AU2002347022A1 (en) 2001-12-20 2003-07-09 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
PL210413B1 (pl) * 2001-12-20 2012-01-31 Wyeth Corp Pochodne indoliloalkiloaminy
CA2487211C (en) 2002-06-04 2010-09-14 Neogenesis Pharmaceuticals, Inc. Pyrazolo(1,5a) pyrimidine compounds as antiviral agents
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
US20050075331A1 (en) * 2003-10-06 2005-04-07 Pratt John K. Anti-infective agents
DE10253426B4 (de) * 2002-11-15 2005-09-22 Elbion Ag Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
US7151114B2 (en) * 2003-01-09 2006-12-19 Boehringer Ingelheim International Gmbh Use of substituted 2-phenylbenzimidazoles as medicaments
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2004082621A2 (en) * 2003-03-15 2004-09-30 Bethesda Pharmaceuticals, Inc. Novel ppar agonists, pharmaceutical compositions and uses thereof
GB0307891D0 (en) 2003-04-04 2003-05-14 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
WO2004098494A2 (en) 2003-04-30 2004-11-18 Cytokinetics, Inc. Compounds, compositions, and methods
KR101164070B1 (ko) 2003-05-09 2012-07-12 베링거 인겔하임 인터내셔날 게엠베하 Ｃ형 간염 바이러스 ｎｓ5ｂ 폴리머라제 억제제 결합 포켓
CN1829709A (zh) 2003-08-01 2006-09-06 健亚生物科技公司 对抗黄病毒的双环咪唑衍生物
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
GB0321003D0 (en) 2003-09-09 2003-10-08 Angeletti P Ist Richerche Bio Compounds, compositions and uses
GB0323845D0 (en) 2003-10-10 2003-11-12 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329459A (en) * 1980-05-05 1982-05-11 The Upjohn Company Tetrahydrobenzopyran derivatives
RU2193561C2 (ru) * 1991-05-02 2002-11-27 Джон Вайс энд Бразер Лимитед Производные пиперазина, способ их получения, фармацевтическая композиция, промежуточное соединение

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2533825C2 (ru) * 2009-06-11 2014-11-20 Сиена Байотек С.П.А. ПРОИЗВОДНЫЕ БЕНЗИМИДАЗОЛА И ИМИДАЗО[4,5-с]ПИРИДИНА, В КАЧЕСТВЕ АНТАГОНИСТА ПУТИ HEDGEHOG
RU2702906C2 (ru) * 2012-05-30 2019-10-14 Астекс Терапьютикс Лимитед Птеридины в качестве fgfr ингибиторов

Also Published As

Publication number Publication date
NO20061013L (no) 2006-04-28
US20090081165A1 (en) 2009-03-26
TW200517381A (en) 2005-06-01
US20050187390A1 (en) 2005-08-25
KR20060054410A (ko) 2006-05-22
CN1829709A (zh) 2006-09-06
RU2006106272A (ru) 2006-08-27
EP1651631A1 (en) 2006-05-03
ZA200600424B (en) 2007-05-30
BRPI0413234A (pt) 2006-10-03
AU2004261667A1 (en) 2005-02-10
CA2534649A1 (en) 2005-02-10
US7511145B2 (en) 2009-03-31
JP2007501189A (ja) 2007-01-25
WO2005012288A1 (en) 2005-02-10
IL172975A0 (en) 2006-06-11

Similar Documents

Publication Publication Date Title
RU2355687C2 (ru) Бициклические производные имидазола в качестве средства против вирусов семейства flaviviridae
CN101098872B (zh) 可用作蛋白激酶抑制剂的吡咯并吡嗪和吡唑并吡嗪
JP4907082B2 (ja) ウイルス阻害剤
CA2448737C (en) Viral polymerase inhibitors
AU2002313410B2 (en) Hepatitis C virus polymerase inhibitors with a heterobicyclic structure
CN102427729B (zh) 丙型肝炎病毒复制的抑制剂
US20060211698A1 (en) Bicyclic heteroaryl derivatives for treating viruses
WO2002004425A2 (en) Viral polymerase inhibitors
EA019027B1 (ru) Производные флуорена, содержащие их композиции и применение
AU2009222521A1 (en) Nitrogen-containing heteroaryl derivatives for the treatment of HCV-infection
MXPA06000999A (en) Bicyclic imidazol derivatives against flaviviridae
MXPA05013090A (en) Nitrogen-containing heteroaryl derivatives for the treatment of hcv-infection
HK1062299A (en) Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors

Legal Events

Date Code Title Description
PC4A Invention patent assignment

Effective date: 20090826

MM4A The patent is invalid due to non-payment of fees

Effective date: 20100731